| abstract |
The present invention provides a quinoline derivative for treatment of triple-negative breast cancer and use thereof in preparation of a pharmaceutical composition for tumor treatment. In particular, the present invention relates to use of a quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer. (I) |